Blair L DeBuysscher1, Dana Scott2, Andrea Marzi3, Joseph Prescott3, Heinz Feldmann4. 1. Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA; Division of Biological Sciences, University of Montana, Missoula, MT, USA. 2. Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA. 3. Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA. 4. Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA. Electronic address: feldmannh@niaid.nih.gov.
Abstract
BACKGROUND: Nipah virus (NiV), a zoonotic pathogen causing severe respiratory illness and encephalitis in humans, emerged in Malaysia in 1998 with subsequent outbreaks on an almost annual basis since 2001 in parts of the Indian subcontinent. The high case fatality rate, human-to-human transmission, wide-ranging reservoir distribution and lack of licensed intervention options are making NiV a serious regional and potential global public health problem. The objective of this study was to develop a fast-acting, single-dose NiV vaccine that could be implemented in a ring vaccination approach during outbreaks. METHODS: In this study we have designed new live-attenuated vaccine vectors based on recombinant vesicular stomatitis viruses (rVSV) expressing NiV glycoproteins (G or F) or nucleoprotein (N) and evaluated their protective efficacy in Syrian hamsters, an established NiV animal disease model. We further characterized the humoral immune response to vaccination in hamsters using ELISA and neutralization assays and performed serum transfer studies. RESULTS: Vaccination of Syrian hamsters with a single dose of the rVSV vaccine vectors resulted in strong humoral immune responses with neutralizing activities found only in those animals vaccinated with rVSV expressing NiV G or F proteins. Vaccinated animals with neutralizing antibody responses were completely protected from lethal NiV disease, whereas animals vaccinated with rVSV expressing NiV N showed only partial protection. Protection of NiV G or F vaccinated animals was conferred by antibodies, most likely the neutralizing fraction, as demonstrated by serum transfer studies. Protection of N-vaccinated hamsters was not antibody-dependent indicating a role of adaptive cellular responses for protection. CONCLUSIONS: The rVSV vectors expressing Nipah virus G or F are prime candidates for new 'emergency vaccines' to be utilized for NiV outbreak management. Published by Elsevier Ltd.
BACKGROUND:Nipah virus (NiV), a zoonotic pathogen causing severe respiratory illness and encephalitis in humans, emerged in Malaysia in 1998 with subsequent outbreaks on an almost annual basis since 2001 in parts of the Indian subcontinent. The high case fatality rate, human-to-human transmission, wide-ranging reservoir distribution and lack of licensed intervention options are making NiV a serious regional and potential global public health problem. The objective of this study was to develop a fast-acting, single-dose NiV vaccine that could be implemented in a ring vaccination approach during outbreaks. METHODS: In this study we have designed new live-attenuated vaccine vectors based on recombinant vesicular stomatitis viruses (rVSV) expressing NiV glycoproteins (G or F) or nucleoprotein (N) and evaluated their protective efficacy in Syrian hamsters, an established NiV animal disease model. We further characterized the humoral immune response to vaccination in hamsters using ELISA and neutralization assays and performed serum transfer studies. RESULTS: Vaccination of Syrian hamsters with a single dose of the rVSV vaccine vectors resulted in strong humoral immune responses with neutralizing activities found only in those animals vaccinated with rVSV expressing NiV G or F proteins. Vaccinated animals with neutralizing antibody responses were completely protected from lethal NiV disease, whereas animals vaccinated with rVSV expressing NiV N showed only partial protection. Protection of NiV G or F vaccinated animals was conferred by antibodies, most likely the neutralizing fraction, as demonstrated by serum transfer studies. Protection of N-vaccinated hamsters was not antibody-dependent indicating a role of adaptive cellular responses for protection. CONCLUSIONS: The rVSV vectors expressing Nipah virus G or F are prime candidates for new 'emergency vaccines' to be utilized for NiV outbreak management. Published by Elsevier Ltd.
Authors: Stephan Günther; Heinz Feldmann; Thomas W Geisbert; Lisa E Hensley; Pierre E Rollin; Stuart T Nichol; Ute Ströher; Harvey Artsob; Clarence J Peters; Thomas G Ksiazek; Stephan Becker; Jan ter Meulen; Stephan Olschläger; Jonas Schmidt-Chanasit; Hinrich Sudeck; Gerd D Burchard; Stefan Schmiedel Journal: J Infect Dis Date: 2011-11 Impact factor: 5.226
Authors: Jennifer A Schwartz; Linda Buonocore; Amorsolo L Suguitan; Alex Silaghi; Darwyn Kobasa; Gary Kobinger; Heinz Feldmann; Kanta Subbarao; John K Rose Journal: J Virol Date: 2010-02-24 Impact factor: 5.103
Authors: Olivier Escaffre; Tais B Saito; Terry L Juelich; Tetsuro Ikegami; Jennifer K Smith; David D Perez; Colm Atkins; Corri B Levine; Matthew B Huante; Rebecca J Nusbaum; Janice J Endsley; Alexander N Freiberg; Barry Rockx Journal: J Virol Date: 2017-07-12 Impact factor: 5.103
Authors: Gunner P Johnston; Erik M Contreras; Jeffrey Dabundo; Bryce A Henderson; Keesha M Matz; Victoria Ortega; Alfredo Ramirez; Arnold Park; Hector C Aguilar Journal: J Virol Date: 2017-04-28 Impact factor: 5.103
Authors: Brad S Pickering; John M Hardham; Greg Smith; Eva T Weingartl; Paul J Dominowski; Dennis L Foss; Duncan Mwangi; Christopher C Broder; James A Roth; Hana M Weingartl Journal: Vaccine Date: 2016-08-17 Impact factor: 3.641
Authors: Blair L DeBuysscher; Dana P Scott; Rebecca Rosenke; Victoria Wahl; Heinz Feldmann; Joseph Prescott Journal: Cells Date: 2021-05-25 Impact factor: 6.600